Todd Asset Management LLC Purchases 29,808 Shares of Sanofi $SNY

Todd Asset Management LLC grew its stake in Sanofi (NASDAQ:SNY) by 4.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 699,074 shares of the company’s stock after buying an additional 29,808 shares during the quarter. Todd Asset Management LLC’s holdings in Sanofi were worth $32,997,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its position in shares of Sanofi by 5.5% in the third quarter. PNC Financial Services Group Inc. now owns 125,405 shares of the company’s stock valued at $5,919,000 after acquiring an additional 6,517 shares during the last quarter. Aberdeen Group plc increased its stake in shares of Sanofi by 17.7% during the 3rd quarter. Aberdeen Group plc now owns 380,927 shares of the company’s stock worth $17,980,000 after purchasing an additional 57,345 shares during the last quarter. BTC Capital Management Inc. grew its holdings in Sanofi by 12.8% during the third quarter. BTC Capital Management Inc. now owns 29,035 shares of the company’s stock worth $1,370,000 after purchasing an additional 3,304 shares during the period. MidWestOne Financial Group Inc. raised its stake in Sanofi by 90.7% in the third quarter. MidWestOne Financial Group Inc. now owns 29,940 shares of the company’s stock valued at $1,413,000 after buying an additional 14,237 shares during the period. Finally, Assetmark Inc. boosted its stake in shares of Sanofi by 25.0% during the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock worth $16,859,000 after acquiring an additional 71,356 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of several research reports. Wall Street Zen upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Citigroup assumed coverage on Sanofi in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. Guggenheim downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. TD Cowen restated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Finally, Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday. Five analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $62.67.

Sanofi Stock Performance

Shares of Sanofi stock opened at $46.01 on Monday. The firm has a market capitalization of $112.22 billion, a P/E ratio of 12.78, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45. The company has a current ratio of 1.09, a quick ratio of 0.29 and a debt-to-equity ratio of 0.20. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The business’s fifty day simple moving average is $47.73 and its 200 day simple moving average is $48.59.

Sanofi News Summary

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.